An AI-Powered Medicare Benefit Plan: Clover says its Clover Assistant aggregates 100+ clinical and data sources it claims provide real-time guidance to PCPs, driving earlier diagnoses (18-36 months earlier in studies) and reducing hospitalizations, with about 70% of its members being used by physicians.
Profit objectives: Management reports recent EBITDA profits, expects significant growth (>50%) and expresses confidence in achieving GAAP net income gain in 2026while the guidance also means this year could be the company’s first full year of GAAP profit.
Strong cohort economics and growth levers: Member retention increases 95%the loss per new member declines as affiliates mature and the total cost of care declines, and Clover is scaling its external software business, Counterpart, with the goal of matching its Medicare Advantage membership coverage over the next year to three years.
Interested in Clover Health Investments, Inc.? Here are five stocks we like best.
Clover Health Investments (NASDAQ: CLOV ) executives described what they described as a repeatable, technology-driven medical benefits model at the Leerink Global Healthcare Conference, with high member retention, profitability dynamics, and expanding use cases for its software beyond the company’s own health plan.
Management pitched Clover as an “AI-powered Medicare Advantage plan,” with technology central to the design of its business model for nearly a decade. The company’s approach centers on supporting primary care physicians (PCPs) “at the point of care” with its Clover Assistant platform, which is said to improve clinical outcomes through earlier diagnosis and better treatment while reducing the total cost of care over time.
→ Broadcom’s AI movement may be far from over
The company compared its model to the traditional medical benefit approach, citing a broad network that it says contrasts with the HMO-heavy structure in the market. Clover also said that it does not represent risk, which means that it bears the cost of new members who are unprofitable in the first year, but keeps the full upside as the partners mature.
Clover executives cited member retention of more than 95%, which they identified as market leading, and said the company was the “number one PPO in the nation” in HEDIS quality scores for the second year in a row.
→ Why an upstart bank charter can change everything
Regarding financial performance, the company said that it has been EBITDA profitable for the past few years and reiterated its expectation for significant growth while improving profitability. Executives also said they are “confident” in achieving GAAP net income profit for 2026 while growing “more than 50%,” and said this year is expected to be “the first full year of GAAP net income profit” based on its guidance.
Management described Clover Assistant as connecting to more than 100 medical data sources, including major electronic health records, claims, labs, and pharmacy-related data. Beyond data collection, the executive said the company’s machine learning models synthesize data into real-time recommendations and care management recommendations for physicians, while PCPs are responsible for clinical decisions.
→ Amazon is growing while the market is falling—here’s why
Clover also cited white papers published on chronic conditions including diabetes, congestive heart failure (CHF), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). The executives said the A/B test diagnoses in those studies generally occurred 18 to 36 months earlier for groups supported by Clover Assistant than those that were not, and cited reductions in hospitalizations and readmissions as examples of outcomes used to measure impact.
In discussing profitability by member tenure, management said monthly per-member losses for new members decreased year-over-year, citing acquisition economics and prior care management involvement — particularly for high-velocity members. For returning members, Clover said the economics of the model are “very strong,” with margins expanding as the group matures and the total cost of care decreases over time. When asked about predictability, the CEO said the coordination function is “directly predictable” and “runs like clockwork.”
Clover added that while about 70% of its total membership is covered by physicians using Clover Assistant, about 30% is currently not covered by PCPs using the software. The company said it expects to maintain coverage percentages even as it scales membership.
Discussing the latest Annual Enrollment Period (AEP), management said 85% of new members were “switchers” with medical histories that could be obtained from previous plans, which it said was nearly 500 basis points higher than the previous AEP. The executive said basic membership indicators, including January and February payouts and filings related to risk adjustment, were in line with expectations.
Regarding the price for the 2026 bid, Clover said that it is applying the discipline of underwriting and does not accept the development in the trend. Executives noted that the company’s medical cost trend (part C excluding pharmacy) was slightly below 5% last year and said it was bidding to assume a medical cost trend higher than that level, without disclosing a specific percentage. In pharma, Clover pointed to initiatives around PBM transparency, pricing or rebates, and formulary management, saying it is seeing improvements while the industry is still adjusting to changes related to the Inflationary Reduction Act.
The company also outlined an MD-led home care division for high-acuity members, in which physicians (MDs and DOs) take over primary care and conduct in-home visits while using the same Clover Assistant platform. Management positions it as a differentiator that supports better health outcomes.
For 2026, Clover said it expects a four-star payoff year, calling it a tailwind but insisting it designed its model to be “efficient and profitable” even at 3.5 stars and not dependent on four-star status. The CEO said the increase in quality bonus payments was in line with guidance and was “significant” over the year, although they did not measure it through the flow of benefits trade-offs.
Regarding the Medicare Advantage pricing environment, management said it did not provide specific expectations for the final pricing announcement, but believed it would likely be “slightly higher.” Executives added that they are not counting on annual price increases and suggested that a smarter pricing environment could highlight the strength of the Clover model. Clover also said it believes it is less impacted by the proposed CMS changes related to non-linked chart review because its model is based on and supported by its platform and clinical data.
Separately, Klover discussed its third-party software offering, Counterpart, aimed at other health plans and risk-adjusted providers. Management described progress through a series of adoption metrics—downloading the client’s “logo,” logging into PCP practices, then expanding the number of patients covered by the software and scaling it geographically. While noting it’s not yet material from a revenue perspective, the company reiterated its near-term goal for patients or members covered by the counterparty to equal the number of members in Clover’s own Medicare Advantage plan, describing the timeline as “between” the end of the year and three years out. The CEO also said the company wants to maintain SG&A flexibility to invest more in the counterparty if momentum accelerates, noting that product development and R&D are included in the SG&A classification.
When asked about the case involving the stars, Clover did not provide any updates on the case’s progress.
Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for seniors. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. Using data analytics, Clover Health aims to deliver personalized care pathways and preventative interventions for its members.
At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to generate real-time insights for physicians and care teams.
The article “Clover Health Investments’ AI Medicare Profitability Model, Targets GAAP Profits in 2026 at Leerank Conference” was originally published by MarketBeat.
